TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* MDE as primary diagnosis according to DSM-IV-TR criteria (classification code 296.xx)~* Current MDE duration of at least 3 months and less than 12 months~* The patient has a MADRS total score \>=30~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the DSM-IV TR~* Any substance disorder within the previous 6 months~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication 2 weeks prior to screening and during the study~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine (Lu AA21004) 5 mg (Type: EXPERIMENTAL): None
- Vortioxetine (Lu AA21004) 10 mg (Type: EXPERIMENTAL): None
- Venlafaxine XL 225 mg (Type: OTHER): Active Reference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with B-precursor ALL in complete hematological remission after at least 3 intense chemotherapy blocks~* Presence of minimal residual disease at a level of ≥ 10\^-3~* Availability of bone marrow specimen from primary diagnosis for clone-specific MRD assessment~* Negative human immunodeficiency virus (HIV) test, negative hepatitis B (HbsAg) test and hepatitis C virus (anti-HCV) test~* Negative pregnancy test in women of childbearing potential~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Presence of circulating blasts or current extra-medullary involvement by ALL~* History of relevant central nervous system (CNS) pathology or current CNS pathology~* Prior allogeneic hematopoietic stem cell transplant (HSCT)~* Eligibility for treatment with tyrosine-kinase inhibitors (TKI)~* Systemic cancer chemotherapy within 2 weeks prior to study treatment~* Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment~* Previous treatment with blinatumomab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cancer and planned to receive chemotherapy in 1, 2, 3, or 4 weekly schedules for a minimum of 8 weeks~* have a hemoglobin level of \>10 grams per deciliter and \<= 12 grams per deciliter within 14 days before the start of the first on-study chemotherapy cycle~* Eastern Cooperative Oncology Group (scale used by researchers to represent the level of activity a patient is capable of) score of 0 (able to carry out all normal activity without restriction) to 2 (ambulatory and capable of all self-care but unable to carry out any work)~* life expectancy of \>=6 months~* female subjects postmenopausal for at least 1 year, surgically sterile or practicing an effective method of birth control~Exclusion Criteria:~* Clinically significant or uncontrolled disease/dysfunction of any body system that is not due to cancer or chemotherapy, including uncontrolled or severe cardiovascular disease, recent (\< 6 months) myocardial infarction, uncontrolled high blood pressure, congestive heart failure, or uncontrolled or unexplained history of seizures~* planned surgery expected to influence hemoglobin levels, within the first 8 or 9 weeks of study entry~* major illness or infection within 1 month of study entry~* highly increased risk of thrombotic or other vascular events~* androgen therapy within 2 months of study entry~* anemia due to factors other than cancer/chemotherapy (e.g., severe hemolysis, gastrointestinal bleeding, or myelodysplastic syndromes)~* blood transfusion within 14 days prior to study entry~* pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male aged ≥ 35 years~* Type 2 diabetes mellitus~* Symptomatic PAD~* Ankle-brachial index ≤ 0.85 or calcified blood vessels with toe-brachial index ≤ 0.6 and/or abnormal post-exercise ankle-brachial index~* Prior surgical or percutaneous intervention of the peripheral arteries ≥12 months previously with a residual stenoses of ≥50% in a non-dilated artery.~Exclusion Criteria:~* Subject is pregnant or breast-feeding~* Planned revascularization or amputation~* Known bleeding disorder~* History of intracranial hemorrhag3~* Considered at risk of hemorrhagic events~* Hypersensitivity or allergic reactions to aspirin~* Concomitant use of anticoagulants such as warfarin, dabigatran, factor Xa inhibitors or antiplatelet drugs such as clopidogrel, dipyridamole and sulfapyridine~* Subject has a condition or circumstance which would prevent them from adhering to treatment regimens~* Subject has active infection~* Subject has an anemia~* Subject has given blood or received a blood transfusion at any point during the study~* Subject has polycythemia vera or any hyperviscosity syndrome~* Subjects with Waldenstrom's macroglobulinemia who have an increased risk of hyperviscosity syndrome~* Subject has history of severe liver disease, obstructive liver disease such as primary biliary cirrhosis or end-stage renal disease (eGFR \<30 mL/min/m2)~* Family members or employees of the investigator or study centers involved in the study~* Subject has poor diabetes or hypertension control (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin/Ticagrelor placebo (Type: PLACEBO_COMPARATOR): aspirin 81 mg daily and ticagrelor placebo twice daily
- Aspirin/Ticagrelor (Type: ACTIVE_COMPARATOR): aspirin 81 mg daily and ticagrelor 90 mg twice daily
- Aspirin Placebo/Ticagrelor (Type: ACTIVE_COMPARATOR): aspirin placebo daily and ticagrelor 90 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Known castration-resistant disease~* Serum PSA ≥2 ng/mL (μg/L)~* Multiple skeletal metastases (≥2 hot spots) on bone scan~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2.~* Life expectancy ≥6 months~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* History of visceral metastasis, or visceral metastases~* Malignant lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter~* Medical condition that would make prednisone (corticosteroid) use contraindicated~* Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone bid~* Treatment with more than one chemotherapy agent for prostate cancer~* Prior systemic radiotherapy and hemibody external radiotherapy~* History of pituitary or adrenal dysfunction~* Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone)~* Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy~* History of seizures (taking/not taking anticonvulsants), arteriovenous malformation in the brain, head trauma with loss of consciousness~* Central nervous system (CNS) metastases

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) (Type: EXPERIMENTAL): None
- Radium-223 with abiraterone&prednisone (Type: EXPERIMENTAL): None
- Radium-223 with enzalutamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Are Two Antidepressants a Good Initial Treatment for Depression?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently depressed (DSM-IV Major Depression, Dysthymia or Depression NOS)~* HAMD-D (21-Item) \> 9~Exclusion Criteria:~* Prior ineffective adequate trial on either study medication ($ 4 weeks on either escitalopram \>20 mg/d or bupropion \>300 mg/d; \>4 weeks on citalopram \>40 mg/d)~* History suggesting increased risk for Seizures (e.g., prior Seizure as an adult, diagnosed Seizure Disorder, taking medication known to increase seizure risk, history of significant head trauma, history of Bulimia or Anorexia)~* History of intolerance to either study medication unless patient and M.D. agree side effect is probably manageable~* Alcohol and/or drug abuse/dependence during past year~* Major medical problems that are not well controlled (e.g., untreated hypertension or diabetes)~* Bipolar I, Bipolar II~* History of Psychosis, or current Psychosis~* Currently taking antidepressants or mood stabilizers, which is judged unwise to discontinue (occasional sleep medication or benzodiazepine for Anxiety is allowed)~* Not currently depressed (whether considered due to current treatment or not)~* Active suicidal risk (history of suicide attempts will be evaluated on a case by case basis)~* Pregnant or breast-feeding~* Premenopausal women not using known effective birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram + bupropion (Type: EXPERIMENTAL): patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~1. Subjects who had type 2 diabetes treated with diet and exercise only for at least 2 weeks prior to randomization, or who were previously or currently treated with an oral agent and had not responded to diet, exercise, and oral therapy for at least 3 months (documented by an HbA1c \>7.5%).~2. Subjects who completed glimepiride pharmacokinetic Study HOE 490/4045 at preselected sites within 3 weeks prior to the screening period were also permitted to enroll.~3. Subjects were required to be negative for islet cell antigen (ICA) and glutamic acid decarboxylase (GAD) autoantibodies and to have a C-peptide level at 90 minutes of ≥ 1.5 ng/mL. The HbA1c was required to be \>7.1% at screening and \<12.0% on the day of randomization.~EXCLUSION CRITERIA:~Subjects meeting any of the following criteria were not to be included in the study:~1. A history of an acute metabolic complication such as diabetic ketoacidosis within 3 months before screening~2. On insulin therapy, or had received insulin for \>6 weeks, 3 months prior to randomization~3. On weight-reduction medication~4. Known hypersensitivity to biguanides, sulfonamides, or insulin~5. Pregnant or lactating females~6. Clinically significant renal (serum creatinine level \>1.0 mg/dL) or hepatic disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>2.5 times the upper limits of normal \[ULN\])~7. GI disorders that may interfere with the absorption of the study drugs~8. Chronic use of medications known to affect glucose levels such as intermittent use of systemic corticosteroids or large dose of inhaled steroids~9. Clinically significant laboratory abnormality on screening laboratory tests or any medical condition that in the opinion of the investigator would affect the outcome of the study~10. History of drug or alcohol abuse~11. Treatment with any investigational product in the last 3 months before study entry~12. History of noncompliance with regard to follow-up medical care~13. Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 65 years or older~* Diagnosed with osteoporosis (Bone Mineral Density (BMD) T-score \<= -2.5 at spine or hip) or prior fragility fracture BMD T-score \<=-1.5 in at least one of the anatomic sites including lumbar spine, total hip, and femoral neck sites~* Postmenopausal~* Low levels of vitamin D as measured 25-hydroxyvitamin D~* Has fallen at least once within the past 12 months~Exclusion Criteria:~* Unable to stand or sit upright for at least 30 minutes~* Has a bone disorder other than osteoporosis~* Contraindication to the use of FOSAVANCE

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOSAVANCE 5600 (Type: EXPERIMENTAL): alendronate sodium (+) cholecalciferol
- Referred-Care Model (Type: OTHER): Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (Steps 1 and 2).~2. Modified Hoehn and Yahr in the OFF state of II-IV.~3. Treated with levodopa/carbidopa for at least one year with a stable regimen for 4 weeks prior to randomization.~4. Taking at least 4 doses of levodopa/carbidopa per day (3 doses if at least 2 doses contained slow-release formulation) with predictable end of dose wearing off.~5. Successfully competed Parkinson's disease patient diary training with at least 120 minutes of OFF time per day.~6. Stable regimen of other antiparkinson's medications for 4 weeks prior to randomization.~7. At least 30 years of age and able to give written informed consent.~Exclusion Criteria:~1. Treatment with liquid levodopa/carbidopa within 4 weeks of randomization.~2. Treatment with MAO inhibitors except selegiline.~3. Treatment within 3 months with centrally acting dopamine antagonists (6 months for depot formulations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine.~4. Neurosurgical operation for Parkinson's disease.~5. Atypical parkinsonism or secondary parkinsonism variants.~6. Diagnosis of cancer or evidence of continued disease within 5 years.~7. Clinically significant illness of any organ system (e.g., ALT or AST \> 1.5 times the upper limit of normal).~8. Mini-Mental Status Examination score of 25 or less.~9. History of drug or alcohol abuse or dependence within 2 years.~10. History of psychotic illness or seizures.~11. Clinically relevant depression disorder.~12. History of neuroleptic malignant syndrome.~13. Pregnancy or lactation. Women of child bearing potential must use a reliable method of contraception.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* complicated intra-abdominal infections~Exclusion Criteria:~* infections limited to hollow viscus~* ischemic bowel disease without perforation~* acute suppurative cholangitis~* acute necrotizing pancreatitis~* pts to undergo stated abdominal repair, open abdomen technique or marsupialization~* Apache II \>25

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NXL104/CAZ/MTZ (Type: EXPERIMENTAL): NXL104/ceftazidime + metronidazole
- Meropenem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with DIE and having received surgery treatment within one month before inclusion~* Premenopausal women aged \>=18 years old.~* Written ICF has been obtained prior to any study-related procedures~* Patient for whom the treating physician already made the decision to treat by Diphereline.~* Patient should be mentally and physically able to express her symptom complaints and answer questions.~Exclusion Criteria:~* Pregnancy or lactation.~* Patients currently on treatment or who have been on therapy with a GnRHa in the last 6 months.~* Premenopausal women who may reach menopause within the 3 years post randomisation.~* Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg~* Treatment with another research drug over the last 3 months before the study~* Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep Infiltrating Endometriosis (DIE) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)~* Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20~* Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4.~Exclusion Criteria:~* Significant risk of suicide as assessed by clinician judgment, HAM-D17 and Columbia Suicide-Severity Rating Scale scores.~* Past treatment with desvenlafaxine succinate sustained release.~* Other eligibility criteria also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine succinate sustained release 50 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete